04/2024. Long-term clinical impact of MV140

Dr. Bob Yang (Royal Berkshire NHS Foundation Trust, UK) presented initial results from the first long-term (9-years) follow-up study of MV140 (Uromune®) at the annual congress of the European Association of Urology (EAU24) in Paris.  

The results show that more than half (54%) of the 89 patients (72 women and 17 men) who were followed for 9 years after treatment with MV140 remained free of UTIs (mean time free 4.5 years). These patients were initially enrolled in a first UK study with MV140 because of recurrent UTIs (more than 3 episodes per year).

These results have been highlighted elsewhere and are consistent with previous follow-up studies (3-years) with MV140, further supporting its durable effect in various clinical settings.

MV140 is a sublingual mucosal vaccine developed by INMUNOTEK that contains the bacteria responsible for most urinary tract infections and has demonstrated clinical efficacy in a number of clinical trials.

+ info